Seeking Alpha

Seeking Alpha Portfolio App for iPad

KLLJ Investments

KLLJ Investments picture

KLLJ Investments

Profile

Send Message

View as an RSS Feed

View KLLJ Investments' Articles BY TICKER:

Arena: The Belviq Launch And Why The Short Thesis Is Wrong
on Sun, Apr 14 • VVUS, ARNA • 80 Comments
Arena's Recent Outperform Call And A Probability Weighted Valuation
on Fri, Feb 8 • VVUS, ARNA • 14 Comments
Arena Breaking Out Ahead Of European Approval
on Wed, Jan 9 • VVUS, ARNA • 50 Comments
The Approaching Arena Battle
on Wed, Dec 19, 2012 • ARNA • 26 Comments
Assessing Arena's Belviq As A Diabesity Drug
on Wed, Dec 12, 2012 • ARNA • 37 Comments
Important Insights For Arena Pharmaceuticals
on Thu, Nov 8, 2012 • ARNA • 18 Comments
Are Qsymia's Launch Challenges A Category Problem?
on Tue, Nov 6, 2012 • ARNA, VVUS • 24 Comments
The Vivus Exit Continues
on Wed, Oct 31, 2012 • ARNA, VVUS • 79 Comments
Is Arena The Next Alexion?
on Thu, Sep 27, 2012 • ALXN, ARNA • 97 Comments
A Valuation Model For Arena's Belviq
on Thu, Aug 2, 2012 • VVUS, ARNA • 110 Comments
Why Analysts Still Have It Wrong With Arena
on Mon, Jul 2, 2012 • VVUS, ARNA • 81 Comments
Is Arena Still A Speculative Stock?
on Fri, Jun 1, 2012 • VVUS, ARNA • 48 Comments
Preview Of Arena's Upcoming Advisory Committee
on Mon, May 7, 2012 • VVUS, ARNA • 17 Comments
Arena Pharmaceuticals' Lorcaserin Will Be A Blockbuster Drug
on Wed, Feb 29, 2012 • VVUS, ARNA • 48 Comments
Weight Loss Drugs: Why Arena's Is Likely To Win Approval Before Vivus's
on Wed, Feb 22, 2012 • VVUS, ARNA • 30 Comments
Is Arena's Lorcaserin On Track For Approval In 2012?
on Mon, Sep 12, 2011 • ARNA • 45 Comments
VirnetX Is on Fire: Join the Party Before It's Too Late
on Thu, Jun 2, 2011 • MSFT, CSCO, AAPL • 15 Comments
Sangamo BioSciences' Platform Could Be the Future of Biotech
on Tue, Feb 1, 2011 • SGMO • 13 Comments
MannKind's Path Forward
on Thu, Jan 20, 2011 • MNKD • 25 Comments
MannKind’s Afrezza Has Mega-Blockbuster Potential
on Mon, Dec 13, 2010 • MNKD • 45 Comments
Clearing Up the Uncertainty Around MannKind’s Afrezza
on Wed, Dec 8, 2010 • MNKD • 69 Comments
Afrezza’s Market Potential and the Future Value of MannKind
on Fri, Nov 12, 2010 • MNKD, CELG, DNDN • 39 Comments
Lorcaserin’s Path to Approval
on Mon, Oct 25, 2010 • ARNA • 9 Comments
What Analysts Won't Tell You About Arena
on Tue, Sep 7, 2010 • ARNA, VVUS, OREX • 60 Comments
Is Lorcaserin the New Miracle Drug?
on Fri, Aug 6, 2010 • ARNA • 29 Comments
Is Mannkind the Next Takeover Target?
on Sun, Jul 25, 2010 • MNKD, DNDN, BIIB • 26 Comments
Arena Inks a Potential Blockbuster Deal
on Thu, Jul 1, 2010 • ARNA, VVUS • 14 Comments
MannKind Bear Analysts Strike Again
on Wed, Jun 16, 2010 • MNKD, LLY • 12 Comments
A Giant Leap for MannKind
on Mon, May 24, 2010 • MNKD, PFE, NVO • 17 Comments
Vivus: Is the Ship Sinking?
on Fri, May 21, 2010 • VVUS • 21 Comments
Is Arena’s Lorcaserin More Valuable Than Dendreon’s Provenge?
on Fri, May 14, 2010 • ARNA, DNDN, JNJ • 53 Comments